Humana Inc. (NYSE:HUM) Holdings Decreased by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB cut its position in shares of Humana Inc. (NYSE:HUM) by 3.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,901 shares of the insurance provider’s stock after selling 91 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Humana were worth $736,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Apollon Wealth Management LLC lifted its position in shares of Humana by 6.0% in the 4th quarter. Apollon Wealth Management LLC now owns 2,983 shares of the insurance provider’s stock worth $757,000 after buying an additional 168 shares during the last quarter. Austin Asset Management Co Inc raised its stake in Humana by 7.8% during the fourth quarter. Austin Asset Management Co Inc now owns 1,081 shares of the insurance provider’s stock worth $274,000 after acquiring an additional 78 shares during the period. Cidel Asset Management Inc. raised its stake in Humana by 18.4% during the fourth quarter. Cidel Asset Management Inc. now owns 1,870 shares of the insurance provider’s stock worth $474,000 after acquiring an additional 290 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Humana by 1.7% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 330,906 shares of the insurance provider’s stock worth $83,954,000 after acquiring an additional 5,497 shares during the last quarter. Finally, Choreo LLC boosted its stake in Humana by 17.4% in the fourth quarter. Choreo LLC now owns 6,711 shares of the insurance provider’s stock valued at $1,706,000 after acquiring an additional 995 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on HUM. Piper Sandler raised their price target on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. Morgan Stanley raised their target price on Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Barclays upped their price target on shares of Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 22nd. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and lifted their price objective for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Finally, Wells Fargo & Company decreased their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $297.68.

Insider Activity at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.32% of the company’s stock.

Humana Price Performance

Shares of NYSE HUM opened at $266.91 on Tuesday. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The firm has a 50-day moving average of $274.21 and a two-hundred day moving average of $297.52. The company has a market capitalization of $32.14 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 2.11 and a beta of 0.56.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.